Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 30, 2007

Sapphire Licenses a Novo Nordisk Program Related to Obesity Therapeutics

  • Sapphire Therapeutics licensed a discovery-stage ghrelin antagonist program from Novo Nordisk. These candidates are being researched and developed as potential obesity treatments.

    “Ghrelin, as the only known systemically acting appetite-stimulating hormone, offers a new and very specific target for antagonist drug intervention,” explains William J. Polvino, M.D., Sapphire's president and CEO.

    Sapphire focuses on developing drugs that act on the ghrelin receptor against metabolic and oncologic diseases. “Licensing this promising discovery-stage ghrelin antagonist program from Novo Nordisk complements Sapphire's clinical-stage agonist program and increases the breadth of our ghrelin portfolio,” Dr. Polvino adds. Thus far, the company has a Phase II candidate being tested in cancer patients with anorexia/cachexia syndrome and ipamorelin and  a compound in Phase I/II studies in postoperative ileus.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »